Trial Profile
A Phase II, Multicenter, Randomized and Controlled Open-Label Trial Comparing the Safety and Efficacy of Bilateral Intraputaminal (IPu) Administration of CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN]) Combined with Best Medical Therapy (BMT) versus BMT-alone in Subjects With Idiopathic Parkinson's Disease
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 04 Apr 2016
Price :
$35
*
At a glance
- Drugs CERE 120 (Primary) ; Antiparkinsonians
- Indications Parkinson's disease
- Focus Therapeutic Use
- Sponsors Ceregene
- 19 Oct 2011 New trial record